Indoco Remedies Other Announcement
Indoco Remedies disclosed an unsolicited Crisil ESG rating of 'Crisil ESG 60'. The company notes it did not engage Crisil for the assessment.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements with these filters
Indoco Remedies disclosed an unsolicited Crisil ESG rating of 'Crisil ESG 60'. The company notes it did not engage Crisil for the assessment.
Indoco Remedies will incorporate a new wholly owned subsidiary, Warren Lifesciences Private Limited, for the pharmaceutical business with an initial capital of Rs. 1 Lakh.
Indoco Remedies filed proceedings of its 79th AGM held on 17 September 2026. Shareholders voted on nine resolutions including dividend and borrowing limits.
Indoco Remedies promoter Aditi M. Panandikar and PAC bought 38,930 shares on the open market, raising aggregate holding to 7.30%. No transaction price is disclosed in the filing.
Promoters Aditi M. Panandikar, Madhura Suresh Kare, Suresh G. Kare, and Aruna Suresh Kare acquired Indoco Remedies Ltd shares via market purchases, totaling ₹0.92 Crore.
Indoco Remedies received seven USFDA observations in Form 483 for its Plant II (Sterile) facility in Goa following an inspection from August 27 to September 4, 2026.
Promoters Aditi M. Panandikar and Madhura Suresh Kare each purchased 2,000 shares of Indoco Remedies from the open market. This reflects an increased promoter stake.
Promoters Aditi M. Panandikar and Madhura Suresh Kare acquired 10,000 equity shares of Indoco Remedies Limited. This open-market purchase increases the promoter group stake from 5.85% to 5.86%.
Promoters Aditi M. Panandikar and Madhura Suresh Kare acquired a total of 10,000 equity shares of Indoco Remedies Ltd through market purchases.
Indoco Remedies Limited has executed a Deed of Conveyance to sell a plot of land located at Mahal Industrial Estate to Kalpataru Townships Private Limited.
Indoco Remedies has executed a deed of conveyance to sell a land plot in Mumbai for a total consideration of ₹64 Crore.
Indoco Remedies has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-2026. The report provides disclosures on ESG, operations, and governance.
Indoco Remedies Limited has scheduled its 79th Annual General Meeting for September 17, 2026. The company also released its comprehensive Annual Report for the 2025-26 financial year.
Indoco Remedies Limited fixed September 10, 2026, as the record date for a final dividend of Rs. 0.20 per share. The 79th AGM is scheduled for September 17, 2026.